Cutaneous adverse reactions to lenalidomide

Allergol Immunopathol (Madr). 2015 Jan-Feb;43(1):88-91. doi: 10.1016/j.aller.2013.07.005. Epub 2013 Oct 25.

Abstract

Lenalidomide is an immunomodulatory drug (IMiD) used principally in the treatment of multiple myeloma (MM), myelodysplastic syndromes (MS) and amyloidosis. Adverse reactions related to lenalidomide include myelosuppression (mainly neutropenia but also thrombocytopenia), gastrointestinal problems, skin eruption, atrial fibrillation and asthenia, decreased peripheral blood stem cell yield during stem cell collection, venous thromboembolism, and secondary malignances. In this review we focused our attention on the cutaneous adverse reactions to lenalidomide.

Keywords: Adverse cutaneous reactions; Amyloidosis; Erythema multiforme; Immunomodulatory drugs; Lenalidomide; Multiple myeloma; Myelodisplastic syndromes; Stevens–Johnson syndrome; Toxic epidermal necrolysis.

Publication types

  • Review

MeSH terms

  • Amyloidosis / complications
  • Amyloidosis / drug therapy*
  • Animals
  • Drug Eruptions / etiology
  • Drug Eruptions / prevention & control*
  • Humans
  • Lenalidomide
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Myelodysplastic Syndromes / complications
  • Myelodysplastic Syndromes / drug therapy*
  • Skin / drug effects*
  • Skin / pathology
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Thalidomide
  • Lenalidomide